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REVIEW

Global Epidemiology of Lung Cancer
Julie A. Barta*, Charles A. Powell† and Juan P. Wisnivesky†,‡
While lung cancer has been the leading cause of cancer-related deaths for many years in the United
States, incidence and mortality statistics – among other measures – vary widely worldwide. The aim of
this study was to review the evidence on lung cancer epidemiology, including data of international scope
with comparisons of economically, socially, and biologically different patient groups. In industrialized
nations, evolving social and cultural smoking patterns have led to rising or plateauing rates of lung cancer
in women, lagging the long-declining smoking and cancer incidence rates in men. In contrast, emerging
economies vary widely in smoking practices and cancer incidence but commonly also harbor risks from
environmental exposures, particularly widespread air pollution. Recent research has also revealed clinical,
radiologic, and pathologic correlates, leading to greater knowledge in molecular profiling and targeted
therapeutics, as well as an emphasis on the rising incidence of adenocarcinoma histology. Furthermore,
emergent evidence about the benefits of lung cancer screening has led to efforts to identify high-risk
smokers and development of prediction tools. This review also includes a discussion on the epidemiologic
characteristics of special groups including women and nonsmokers. Varying trends in smoking largely
dictate international patterns in lung cancer incidence and mortality. With declining smoking rates in
developed countries and knowledge gains made through molecular profiling of tumors, the emergence of
new risk factors and disease features will lead to changes in the landscape of lung cancer epidemiology.
Burden of Disease
Internationally, lung cancer continues to be the leading
cause of cancer-related deaths in men and women [1]. A
breakdown by level of economic development shows no
differences in cancer deaths in men but a higher rate of
lung cancer deaths in women in industrialized countries
as compared with developing nations. Among females
in developing countries, lung cancer deaths lag behind
those due to breast cancer [2]. Lung cancer incidence and
mortality are tightly linked to cigarette smoking patterns.
As smoking rates peak – generally first in men, followed
by women – lung cancer incidence and mortality rise in
subsequent decades before declining following the initiation of comprehensive tobacco control programs [3–5].
These trends have occurred earlier in industrialized
countries as compared with the developing world. In the
United States (US) and the United Kingdom (UK), lung
cancer incidence and mortality rates have in fact been
falling since the 1990s. In contrast, emerging nations –
including Brazil, Russia, India, China, and South Africa
(BRICS) – continue to have high rates of cigarette smoking in both men and women. They exhibit a lower inci* Division of Pulmonary and Critical Care Medicine, Sidney
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dence of cancer but a higher mortality burden compared
with developed countries. Reasons for these patterns
include unequal access to healthcare leading to delayed
diagnosis and treatment, environmental contamination,
and sociocultural barriers [6].
Industrialized Countries

In the US, the incidence of lung cancer in men peaked in
the 1980s, followed by a subsequent decline, with similar
patterns in women following 20 years later [7]. Thun et
al. found that in the 1960s, the relative risk of lung cancer death in smokers versus non-smokers was more than
four times higher in men than in women. In the 40 years
since, women’s risk has risen markedly, becoming nearly
identical to that of men [3, 8]. Lung cancer deaths in men
are now declining at an average of 2.9% annually with a
percent decrease roughly double that of women [7]. With
regard to differences between racial and ethnic groups,
non-Hispanic whites and blacks have the highest incidence and death rates [9]. In particular, black men have
the highest mortality, approximately double that of Asian
Americans, the group with the lowest cancer-specific mortality [7, 10]. These racial and ethnic disparities are largely
due to differences in cigarette smoking prevalence, as
well as lower rates of resection and higher probability of
advanced stage at diagnosis in minorities [11–13].
The UK has similar smoking and lung cancer incidence
trends to the US. Male smoking prevalence peaked in the
1940s to 1950s, followed by a peak in lung cancer incidence in the 1970s. Despite declining rates in both sexes,
lung cancer remains the second most common malignancy in the UK [14]. Mainland Europe exhibits wide
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geographic variations in lung cancer incidence (Figure 1).
In general, rates are highest in central and eastern Europe,
but incidence throughout the continent has been declining in men since the early 1990s. Exceptions include
Norway, Finland, Spain, and France, where lung cancer
rates have remained stable. In women, rising lung cancer
incidence has slowed in the US and UK, but rates continue
to increase in central and eastern Europe [15–20]. These
regional differences reflect earlier stages of the tobacco
epidemic in countries such as Belarus, Hungary, Poland,
and the Russian Federation [4, 5, 15, 17]. Additionally,
socioeconomic and educational inequalities, as well as
diagnosis at later stages of disease, contribute to variability in lung cancer incidence and mortality within Europe
[21, 22]. Finally, similarly to the US, lung cancer survival
is lower than that of any other common malignancies in
Europe. EUROCARE-5 reported a mean five-year survival
of 13% for all lung cancer patients diagnosed in 2000–
2007, with a range from 9% in the UK and Ireland to 15%
in central Europe [23, 24].
In Asia, Japan has high incidence and mortality rates
from lung cancer, comparable to those of the US and
Europe [25]. Men have had a higher incidence of lung
cancer than women since the 1970s and continue to comprise the majority of new lung cancer cases in Japan today,
largely due to gender differences in smoking prevalence
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[26]. Conversely, mortality rates in women are lower in
Japan than in other industrialized nations, perhaps due to
the higher incidence of adenocarcinomas with mutations
responsive to targeted therapies [27].
Emerging Economies

Brazil, Russia, India, China, and South Africa are recognized by their large and fast-growing economies [28]. One
of the few South American countries with a cancer registry is Brazil, where tobacco smoking peaked in the 1970s
and lung cancer mortality in men peaked in 1993 and
continues to rise among women [29, 30]. Likewise, in the
Russian Federation, all-cause mortality in men is largely
attributed to very high rates (60%) of both smoking and
alcohol consumption, which are much lower in women
[6]. Accordingly, Russia has among the highest lung cancer mortality rate in men of all European countries but
among the lowest in women. Mortality is now declining,
after peaking in the early 1990s, but tobacco use remains
a major barrier to effective cancer control [16]. Additional
risk factors in Russia include environmental pollution and
workplace exposures in nuclear facilities and asbestos
mines [6].
Comparatively, lung cancer incidence and mortality rates
in India are among the lowest in the world [4]. The most
common cancers in men are head and neck, gastric, and

Figure 1: Global lung cancer incidence and mortality. Global age-standardized incidence and mortality rates for lung
cancer, 20 countries with the highest rates internationally. Reproduced from GLOBOCAN 2012 data with permission.

Barta et al: Global Epidemiology of Lung Cancer

esophageal cancers, attributed to high usage of smokeless tobacco; the most common cancers among women
are cervical and breast. One study in northern India noted
that squamous cell lung cancer was the most common
histology overall and among smokers [31]. While cigarette
smoking has a reported prevalence ranging from 28 to
57% among men, bidi smoking (hand-rolled tobacco) is
the most commonly used (92%) tobacco product [32].
In 2005, the total number of new lung cancer cases in
China was over 500,000. According to GLOBOCAN 2012,
lung cancer is the most common malignancy and cause
of cancer mortality in China, representing 21% of all cancers and 27% of all cancer-related deaths [6]. Lung cancer incidence and mortality is higher in eastern China
and in urban areas, which has been attributed to westernization of lifestyle [33]. However, mortality rates are
increasing faster in rural areas due to poor access to care
[6]. Additionally, age-adjusted mortality rates are higher
in Chinese men – 68% of whom are smokers – but lung
cancer incidence rates are rising faster in women [34]. Risk
factors among Chinese women include secondhand smoking, air pollution, and domestic use of biomass fuels [35].
Developing Countries

Reporting of cancer epidemiology in Africa is limited by
the lack of reliable registries. Among countries on the
African continent as whole, both incidence and mortality rates are low – lung cancer was the fifth most common site of cancer in African men and not even in the top
10 for women. This is likely due to the low prevalence of
smoking (10% in men and <2% in women) as well as the
lower life expectancy of the population. Lung cancer does
have a high incidence in certain regions including the
northern African countries of Western Sahara, Morocco,
Algeria, Tunisia, and Libya, and it is the leading cause of
cancer death in men in northern and southern Africa [36].
South America has a wide range of lung cancer incidence across countries and markedly higher rates in men
compared with women. The highest incidence and mortality in men can be found in Uruguay and in women of
Venezuela and Argentina. Less populated countries such
as Ecuador, Bolivia, and Guyana have very low age-standardized rates, just higher than those of central Africa and
the Middle East [25].
The remainder of Asia has extremely diverse lung cancer
incidences, which are nevertheless consistent within different regions. Asian countries closest to Eastern Europe
such as Armenia, Turkey, and Kazakhstan have among the
highest rates of lung cancer in the world. Korea and southeast Asia have slightly lower rates, and Middle Eastern
countries including Yemen and Saudi Arabia have among
the lowest lung cancer incidence rates in the world [25].
These notable regional differences reflect geographic
trends in the tobacco epidemic [37].
Histopathology
Lung cancer was traditionally classified into two primary
groups, small versus non–small cell type. This grouping
was progressively specified with the use of histopathologic features and immunohistochemical markers, and
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now inroads are being made in distinguishing invasive
adenocarcinomas from pre-invasive lesions. Moreover,
further knowledge about the molecular characteristics
of lung cancers and the availability of targeted therapies has substantially impacted the classification of lung
cancers.
Histology

Adenocarcinoma is the most common histologic subtype of lung cancer in men and women [38]. Prior to the
1990s, squamous cell lung carcinoma was the most common histologic subtype, particularly among men. Since
then, the incidence of adenocarcinoma rose to be greater
than that of squamous cell carcinomas in the US, Canada,
many European countries, and Japan [26, 39]. However,
this switch has not yet been observed in other countries
such as Spain and the Netherlands [39]. The higher rates
of adenocarcinoma relative to squamous and small cell
lung cancer are greater in women [4]. Consequently, the
proportion of adenocarcinomas is rising in many countries in parallel to increased incidence of lung cancer in
women. These findings may reflect differences in the
types of cigarettes (including filtered and low-tar versions) more frequently used by women as well as genetic
predisposition and environmental exposures in female
never-smokers [39].
In 2011, the International Association for the Study of
Lung Cancer, American Thoracic Society, and European
Respiratory Society proposed a new adenocarcinoma categorization based upon histological evidence of invasion.
Preinvasive lesions are classified on a continuum from
atypical adenomatous hyperplasia (AAH) to adenocarcinoma in situ (AIS), and minimally invasive adenocarcinoma (MIA) includes small (<3 cm) lesions with ≤5 mm
of invasion. Invasive adenocarcinomas include a variety
of patterns (e.g., lepidic predominant adenocarcinoma
[LPA], acinar, papillary, micropapillary, and solid) characterized by tumor disruption of >5 mm of the alveolar
basement membrane. This grouping correlates with clinical outcomes, with pre-invasive lesions having an indolent
clinical course with almost 100% curability, in contrast
to invasive carcinomas, which have a considerably worse
prognosis [40]. Recent studies have shown AIS, MIA, and
LPA to have a higher incidence in Japan compared with
western populations [27].
Squamous cell lung cancer is the second most common
subtype, comprising approximately 20% of primary lung
neoplasms in the US. These tumors are distinguished histologically by squamous pearl formation, keratin production, and intercellular bridging. Historically, squamous
cell lung cancer occurred more commonly as central
lesions, but peripheral tumors are rising in incidence [41].
Small cell lung cancer, which has an aggressive clinical
course, comprises 14% of lung cancers and typically presents as a perihilar mass with early and extensive lymph
node metastases. It has a strong association with smoking
history and commonly causes paraneoplastic syndromes.
Less frequent histologic subtypes of lung cancer include
large cell (3%), adenosquamous (1–2%), and carcinoid
tumors (1–2%) [41].
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Molecular Markers

The most common genetic alterations in lung adenocarcinoma are epidermal growth factor receptor (EGFR) and
KRAS activating mutations (Figure 2). EGFR insertions
and deletions are found in roughly 15% of lung adenocarcinomas in the US, with increased frequency in nonsmokers (43% vs. 11% in smokers) [42] and Asians (up to
60% in Asian women) [43]. In advanced stages of disease,
this mutation predicts a more favorable prognosis and
sensitivity to EGFR tyrosine kinase inhibitors (TKIs) such
as erlotinib, gefitinib, and afatinib [44]. Conversely, KRAS
mutations occur more commonly in smokers and appear
to confer worse prognosis [42]. While no targeted therapeutics are currently available for this mutation, clinical
trials are in progress to test drugs that target downstream
effectors of activated KRAS [44]. Additional driver mutations in lung adenocarcinoma occur with a frequency of
<1–4%, including ALK gene rearrangements, ROS1 translocations, HER2 mutations, BRAF mutations, and RET
translocations. ALK rearrangement are clinically important however, as this mutation creates a fusion product,
most frequently with EML4, which predicts sensitivity to
ALK tyrosine kinase inhibitors such as crizotinib and ceritinib [44]. Additionally, ALK-positive tumors have been
associated with acinar or solid histological patterns with
signet ring features [45, 46].
Risk Factors and Environmental Exposures
The myriad risk factors for lung cancer most commonly
include lifestyle, environmental, and occupational exposures. The roles these factors play vary depending on
geographic location, sex and race characteristics, genetic
predisposition, as well as their synergistic interactions.
Cigarette Smoking,
E-cigarettes

Secondhand

Smoking,

and

Cigarette smoking is the most recognized risk factor for
developing lung cancer. Since the Surgeon General’s
report on smoking and health in 1964, at which time

52% of American men and 35% of American women were
active smokers, the prevalence of cigarette smoking in US
and consequently lung cancer has markedly decreased
[47]. While nicotine itself is not carcinogenic, there be
as many as 55 substances in cigarette smoke that have
been deemed carcinogenic by the International Agency
for Research on Cancer including polycyclic aromatic
hydrocarbons and 4-(methylnitrosamino)-1-(3-pyridyl)-1butanone (NNK). Their activation leads to the formation
of DNA adducts and subsequent gene methylation, DNA
sequence changes, DNA segment amplification or deletion, or whole chromosome gains or losses [48]. Relative
risk of lung cancer in smokers as compared with smokers varies from 10- to 30-fold, and the degree of risk is
dependent on number of cigarettes smoked daily and
pack-years of smoking. Cigar and pipe tobacco smoking
are also associated with increased odds of developing lung
cancer [49].
Secondhand smoke exposure also leads to a dosedependent risk of lung cancer. Öberg and colleagues studied the effects of environmental tobacco exposure (ETS)
in 192 countries on six continents and found that 40%
of children and 33%–35% of non-smokers are exposed
to secondhand smoke. The highest rates were in Europe,
the western Pacific, and parts of Southeast Asia; the lowest
rates were found in Africa. Over 600,000 deaths worldwide,
most of them in women, were attributable to secondhand
smoking in 2004 [50]. Similar to Öberg’s finding of the
relative risk for lung cancer in adult non-smokers exposed
to secondhand smoke of 1.21 (95% confidence interval
[CI]: 1.13–1.3), many regulatory bodies have reported an
increase in lung cancer risk by 20 to 30% upon exposure
to ETS [51–55]. The largest numbers of estimated deaths
in adults attributable to secondhand smoke, however, are
not due to lung cancer but rather ischemic heart disease
and asthma [50].
Electronic cigarettes have sparked much recent controversy over potential risks from long-term use, as well as
their role in smoking initiation and potentially cessation

Figure 2: Frequencies of common driver mutations in lung adenocarcinoma in the US and Europe. By overall
frequency (A) and population group (B). Data are derived from large clinicopathologic cohort studies published since
2008 and are representative of US and European populations.
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[56]. The 2012 National Youth Tobacco Survey found the
prevalence of ever-use of e-cigarettes among middle and
high school students in the US to be 6.8%, while prevalence among adults in the simultaneous National Adult
Tobacco Survey was 1.9% [57, 58]. Although conventional
cigarette use is far higher (18% among adults), the incidence of e-cigarette use is rising rapidly and has been associated with higher odds of cigarette smoking and lower
odds of abstinence [59, 60]. Even more concerning, early
research has shown that an e-cigarette vapor-conditioned
media induced gene expression patterns in human bronchial epithelial cells concordant with that of cells exposed
to a cigarette smoke-conditioned media [61].
Domestic Biomass Fuels

Unprocessed biomass fuels, including wood, crop residues, dung, and coal, are used by approximately half of the
world’s population for in-home cooking or heating, primarily in eastern and southern Asia [62]. Indoor emissions
in these households contain high concentrations of polycyclic aromatic hydrocarbons, benzene, and other carcinogenic compounds [63]. Several studies have confirmed an
increased lung cancer risk associated with biomass fuels,
with one pooled analysis showing an odds ratio (OR) of
4.93 (95% CI: 3.73–6.52) among coal users in Asia when
compared with nonsolid-fuel users [64, 65]. A meta-analysis including subjects from Europe and North America,
in addition to Asia, reported similar trends in lung cancer
risk with exposure to coal, biomass, and mixed fuels [62].
Additional studies have reported increased risk with bituminous “smoky coal” use compared with anthracite-based
“smokeless coal,” as well as higher risk with domestic exposures in smokers compared with nonsmokers [63, 66].
COPD and other Pulmonary Conditions

While epidemiological studies report that approximately
20–30% of smokers develop COPD and 10–15% develop
lung cancer, COPD is by far the most common comorbidity in patients with lung cancer, with a varying prevalence
between 30 and 70% [67]. A cohort of newly diagnosed
lung cancer cases was reported to have a prevalence of
COPD as high as six-fold greater than matched smokers
without cancer [67]. Additional studies have shown factors
such as increasing degree of airway obstruction, increasing
age, lower body mass index, and a diffusing lung capacity
of carbon monoxide < 80% to be associated with a diagnosis of lung cancer [68]. Furthermore, extent of emphysema on CT is an independent risk factor for lung cancer,
as well as a predictor of cancer-specific mortality [69, 70].
A recent pooled analysis of almost 25,000 cases from the
International Lung Cancer Consortium also showed both
lung cancer incidence and mortality to be significantly
associated with emphysema [71, 72]. Proposed mechanisms for the link between COPD and lung cancer include
matrix remodeling and lung repair processes which lead
to development of epithelial-mesenchymal transition and
carcinogenesis. Additionally, several genome-wide association and candidate gene studies have identified associations between emphysema and lung cancer at several
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chromosomal loci, supporting that susceptibility to lung
cancer may include COPD-related gene variants [73]. In
a large meta-analysis, never-smokers with a history of
chronic bronchitis, tuberculosis, or pneumonia were
found to have an increased risk of lung cancer [71, 74].
Occupational Exposures

Exposure to asbestos is one of the most well-recognized
occupational causes of lung cancer. Workers in asbestos
mining and milling, shipbuilding, construction, textiles
and insulation, and automobile repair are at the highest
risk. Multiple mechanisms exist for carcinogenesis, including induction of oxidative damage and subsequent DNA
deletions, somatic gene alterations, and enhanced delivery of tobacco carcinogens to the airway epithelium [75].
Markowitz and colleagues evaluated 2,377 North American insulators and found increased lung cancer risk to be
associated with asbestos exposure (rate ratio: 3.6, 95% CI:
1.7–7.6) and asbestosis (rate ratio: 7.4, 95% CI: 4.0–13.7),
with synergistic effects in smokers [76]. Diesel exhaust
exposure has also been studied in trucking industry workers and coal miners. The SYNERGY project, a pooled analysis of 11 case-control studies conducted in Europe and
Canada, which included 13,304 cases, showed that cumulative diesel exposure was associated with an increased
lung cancer risk (OR: 1.31, 95% CI: 1.19–1.43) after controlling for other occupational exposures [77]. Similar
findings were obtained in studies conducted in the US
trucking and non-metal mining industries [78–80]. Other
occupations with an increased incidence of lung cancer
include coal-mining [81], asphalt paving with coal tar
exposure [82], chimney sweeping [83], and painting [84]
although the risk appears to be lower than that of asbestos and diesel exhaust. Other organic and metal exposures
that have been associated with lung cancer include beryllium, cadmium, chromium, silica, formaldehyde, benzo[a]
pyrene, nickel, hard metal dust, and vinyl chloride, which
often act synergistically with tobacco smoking [84–86].
Ambient Air Pollution and Other Environmental
Exposures

European and American studies have evaluated the
association of ambient air pollution with lung cancer
risk. The ESCAPE study, an analysis of multiple cohorts
from nine European countries, found particulate matter (PM) concentration in ambient air to be significantly
associated with lung cancer risk (hazard ratio [HR]: 1.22,
95% CI; 1.03–1.45), particularly adenocarcinoma [87].
Studies in Canada [88], the Netherlands [89, 90], and
the UK [91] also found PM with median aerodynamic
diameter less than 2.5 μm (PM2.5), in addition to nitrogen oxides, nitrogen dioxide, and sulfur dioxide to be
associated with greater risk of lung cancer. In the US,
analysis of the Cancer Prevention Study (CPS) II cohort
found an increase in lung cancer mortality with increasing concentrations of PM2.5 in both non-smokers and
smokers [92, 93].
Arsenic occurring naturally in drinking water and food
has been implicated in lung cancer [94, 95]. Heck and
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colleagues evaluated 223 lung cancer cases and found an
OR of 2.75 (95% CI; 1.00–7.57) for small cell and squamous cancers in subjects with increased toenail arsenic
concentration [96]. Residential radon exposure is another
known risk factor for lung cancer. An analysis of the CPS
II cohort demonstrated a significant linear relationship
between radon concentration and lung cancer mortality
[97]. A Spanish case-control study found similar results,
and also noted a strong interaction with tobacco (OR: 2.21
95% CI: 1.33–3.69 in non-smokers vs. OR: 73 95% CI:
20–268 in heavy smokers) [98].
Diet and Nutrition

Fruit and vegetable consumption have been associated
with decreased lung cancer risk in current smokers; ingestion of cruciferous vegetables, in particular, has been
inversely associated with lung cancer risk [99, 100]. An
analysis of 264 lung cancer tissue samples showed differentially expressed miRNAs among subjects with intake
of quercetin-rich versus quercetin-poor fruit and vegetables [101]. Many studies have attempted to evaluate the
effects of vitamin levels and intake on lung cancer risk.
Dietary and supplemental calcium intake has been shown
to be inversely associated with lung cancer risk in female
nonsmokers (HR: 0.66, 95% CI: 0.48–0.91), current smokers, particularly for lung adenocarcinoma [102, 103]. In
addition, total iron intake was inversely associated with
lung cancer risk in women, while total magnesium intake
increased risk in men and current smokers; no significant
association was found between copper, selenium, and zinc
with lung cancer risk. Johansson and colleagues found
elevated serum vitamin B6 and methionine levels associated with a lower risk for lung cancer in never, former,
and current smokers in Europe [104]. Two studies showed
a protective effect in never-smoking women with vitamin D intake ≥ 400 IU/day and with supplemental soy
intake [105, 106]. Conversely, the Alpha-Tocopherol, BetaCarotene Cancer Prevention Study, revealed a greater incidence of lung cancer and overall mortality in male smokers supplemented with 20mg b-carotene daily [107]. and
prompted the US Preventive Services Task Force (USPSTF)
to uphold their recommendation against the use of vitamin E for the lung cancer prevention. Moreover, the USPSTF recently concluded that there is insufficient evidence
to recommend any vitamins, minerals, and multivitamin
supplementation for lung cancer prevention [108].
Genetic Factors

Genetic factors leading to increased susceptibility to lung
cancer have been poorly studied. First-degree relatives of
patients with lung cancer are at increased risk, even after
adjusting for smoking habits [109]. A meta-analysis of 28
case-control studies and 17 observational cohort studies
of individuals with positive family histories found a RR of
1.84 (95% CI: 1.64–2.05) for developing lung cancer [110].
Additionally, genome-wide association studies have suggested susceptibility loci on various chromosomes, including 5p15.33 and 3q28, among others, but later analyses
have not replicated these results [111, 112]. Other studies
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have identified polymorphisms in various enzymes such
as cytochrome p450 enzymes and DNA repair genes [113],
as well as germline mutations in the EGFR [114].
Measures of Lung Cancer Risk and Impact on
Early Diagnosis
Except for smoking cessation, perhaps the highest reduction in lung cancer mortality rates is related to diagnosis
at early stage followed by surgical resection. While chest
X-rays and sputum cytology screening have not shown a
benefit, early detection via low-dose chest tomography
(CT) is now endorsed by the USPSTF [115]. The National
Lung Screening Trial (NLST) compared annual screening
by low-dose chest tomography (LDCT) with chest X-ray
for three years at 33 US medical centers in 53,454 highrisk subjects 55 to 74 years of age with at least 30 packyears of smoking and found a 20% lung cancer mortality
reduction [116]. Ongoing European trials will provide
additional critical information regarding the potential
benefits of lung cancer screening [117, 118]. However, CT
screening is associated with high rates of positive findings
and may lead to identification of some lung cancers with
low aggressiveness [119]. Thus, better risk stratification
using prediction models or biomarkers of lung cancer risk,
as well as a better understanding of the biologic characteristics of aggressive cancers is required to maximize the
benefit of screening.
Even within smokers, lung cancer risk varies considerably based on factors such as age, quantity and duration
of smoking, and environmental exposures [3]. There is
an ongoing effort to stratify lung cancer risk to identify
individuals best suited for lung cancer screening or refine
eligibility for prevention trials. Several models based on
sociodemographic characteristics, smoking, and other
risk factors have been empirically derived using relatively
large cohorts [120, 121]. Among these, the Bach model
was developed using information from 18,172 subjects
in the Carotene and Retinol Efficacy Trial, which followed
heavy smokers and asbestos-exposed workers from 1989
to 1996 [122]. This model was validated in the AlphaTocopherol Beta-Carotene Cancer Prevention Study and
was found to underestimate 10-year absolute lung cancer
risk while having a discriminatory power comparable to
breast cancer risk models [123]. Likewise, the Spitz model
was derived and validated in a cohort of 1,851 lung cancer
patients and 2,001 matched controls from a single tertiary
center. Risk factors among current and former smokers,
including exposure to environmental tobacco smoke,
dust, fumes, chemicals, history of emphysema, and family history of cancer, predict an increased risk for cancer
[124]. Finally, the Liverpool Lung Project model, validated
in multiple independent populations, is based on data
about smoking duration, history of pneumonia or cancer,
family history of lung cancer, and asbestos exposure to
predict five-year lung cancer risk [125, 126].
Recent research has focused on identifying biomarkers
of lung cancer risk, aggressive behavior among early cancers, and prognosis. These biomarkers may be produced by
neoplastic cells themselves, the tumor microenvironment,
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or the host. A variety of methods to identify biosignatures
utilizing tissue- and biofluids-based assays have been tested
and include genome-wide association studies (GWAS), epigenetics, microRNA, and proteomics [127]. Using GWAS,
several single nucleotide polymorphisms (SNPs) have
been identified on specific chromosomal loci – such as
the 15q25 locus – that are associated with tobacco exposure and lung cancer [128]. It remains to be seen whether
these SNPs can be utilized in the clinical setting to assess
lung cancer risk. Recent epigenetic studies have shown
promise in risk stratification, with one case-control study
using methylation of genes in sputum to identify asymptomatic patients with stage I lung cancer [129]. Several
studies have assessed circulating microRNA biomarkers.
A 34-microRNA signature was reported to identify earlystage NSCLC patients with 80% accuracy [130], while others have been shown to predict recurrent disease [131] in
plasma, surgically resected specimens, and in small biopsies [132]. Similarly, a 24-micro RNA signature [133], validated in a correlative study within the MILD CT-screening
trial, was found to reduce by five-fold the false positive
rate after low-dose CT [134]. Finally, serum proteomic signatures have been integrated with CT imaging features to
predict lung cancer diagnosis in subjects with indeterminate lung nodules [135]. A seven-autoantibody signature
has been shown to have high specificity for lung cancerassociated antigens for early detection of lung cancer in
a high-risk population, and also in distinguishing benign
from malignant disease in CT-detected lung nodules; prospective validation is ongoing [136]. Ajona and colleagues
demonstrated that C4d, a degradation product of complement activation, was elevated in tumors, bronchoalveolar
lavage fluid, and plasma samples from stage I–II lung cancer patients compared to controls. Additionally, C4d levels
were associated with worse survival and increased lung
cancer risk in screen-detected lung nodules [137]. Despite
a substantial progress in biomarker discovery, challenges
that remain include selection of appropriate candidate
signatures based on tumor-specificity and high-throughput approaches, genetic heterogeneity of tumors, and
reproducibility in external validation studies [138, 139].
Special Populations
Lung cancer incidence is rising in women and has in fact
more than doubled since the mid1970s. This increase has
been attributed to increased susceptibility in women compared with men, although studies have found conflicting
results. Data from the UK’s Health Improvement Network
showed that female heavy smokers (>20 cigarettes daily)
had a greater odds of developing lung cancer than men
with comparable smoking histories, with an adjusted OR
of 19.2 (95% CI: 17.1–21.3) in women versus 13.0 (95%
CI: 11.7–14.5) in men [140]. However, a large prospective cohort study in the US disputed this increased susceptibility to lung cancer given equal smoking exposure
[141, 142]. Rising rates of lung cancer in women have also
been attributed to genetic variants, environmental exposures, hormonal factors, and oncogenic viruses [141, 143].
The role of reproductive and hormonal factors remains
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controversial, with mixed results in studies evaluating
associations between parity, age at menarche, and menopause. Although multiple case-control studies report
increased lung cancer risk with exogenous hormone
therapy [144–146], prospective cohort studies show equal
lung cancer rates after adjusting for smoking rates [144,
145, 147–150]. HPV infection has been implicated in the
pathogenesis of lung cancer in women in Asia, but in the
US, infection rates in tumors have been much lower [141],
and one Finnish study of 311 women with lung cancer,
found no evidence of increased risk for lung cancer with
HPV 16 and 18 type-specific infections among both nonsmokers and smokers [151]. Finally, with regard to diet, a
Japanese prospective cohort study of 126 newly diagnosed
women with lung cancer found only a trend toward an
association with plasma genistein, an isoflavone found in
soy and previously shown to act as estrogen agonists and
antagonists [152]. Although adenocarcinoma is the most
common histologic subtype in both genders, women have
an even higher predominance of this cell type and have a
higher likelihood of developing adenocarcinoma in situ, a
preinvasive lesion [141]. Additionally, several gender differences in lung cancer mutations have been described.
EGFR mutations are more prevalent in women, especially
in non-smokers [153]. In particular, the L858R mutation
has been shown to be associated with genetic polymorphisms related to estrogen biosynthesis and metabolism
in never-smoking females with lung adenocarcinomas
[153]. In one large study of the molecular epidemiology of
lung cancer, the KRAS G12C mutation, the most common
G>T transversion mutation in smokers, was more frequent
in women, particularly of younger age [42]. Additionally,
women with lung cancer have been shown in multiple
studies to have better survival rates than men across different age groups, disease stage, and treatment types
[3, 141, 154].
Approximately 10 to 20% of lung cancers occur in
never-smokers with a much higher incidence in women
than in men [155]. In fact, in South Asia, it is estimated
that 83% of women with lung cancer may be never-smokers [156]. It is unclear if never-smoking Asian women who
emigrate to the US and adopt western lifestyles continue
to have elevated risks of lung cancer, although prior literature in gastric cancer appears to suggest that risk is environmental in nature [157]. Additional risk factors thought
to contribute to lung cancer in never-smokers are environmental and occupational exposures and genetic susceptibility [156]. Never-smoking women present at a more
advanced stage, and studies from Asia have reported an
earlier age at diagnosis compared with smokers. However,
in the US and Europe, never-smokers and ever-smokers
are diagnosed with lung cancer at a similar age [156].
With regard to histology, never-smokers have a higher
prevalence of adenocarcinoma [156]. Additionally, while
genomic mutations occur more frequently in current and
former smokers compared with never-smokers, the latter
have a higher prevalence of driver mutations including
EGFR and ALK-EML4 [158, 159]. The EGFR mutation via
an exon 19 deletion or exon 21 mutation is found in up
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to 40–60% of never-smokers [42, 43, 160]. HER2 mutations, a member of the EGFR family, also occurs predominantly in never-smokers [44]. In contrast, KRAS and BRAF
mutations occur mainly in former and current smokers
[161]. Moreover, approximately two-thirds of patients
with ALK-EML4 rearrangements are never-smokers [45,
46, 162]. Finally, never-smokers exhibit improved survival
compared with smokers, even after adjusting for known
prognostic factors [156].
Since the advent of antiretroviral therapy in the 1990s,
cancer mortality among human immunodeficiency virus
(HIV) patients has shifted from acquired immunodeficiency syndrome (AIDS)-related malignancies to solidorgan cancers. Lung cancer incidence is increased two- to
four-fold in the HIV-infected population compared with
the general population and occurs with a lower packyear rate of smoking [163–165]. Using the Veterans
Affairs Central Cancer Registry, Sigel et al. found HIV to
be an independent risk factor for the development of
lung cancer, with an incidence rate ratio of 1.7 (95% CI:
1.5–1.9) [166]. Multiple cohorts have shown that there is
no difference in age, stage at presentation, or histology
between HIV-positive and -negative patients [166, 167].
Lung cancer has also been found to be more aggressive
in HIV patients, and positive HIV status has been associated with greater risk of lung cancer-specific mortality
[168]. However, cancer-related survival has been shown
to be better in patients with CD4 counts > 200 cells/mL
[168–170]. Additionally, in subjects undergoing surgical
resection, HIV patients have been found to have worse
post-operative pulmonary and infectious complications as
well as shorter median time to cancer progression [169].
Conclusions
This review has examined international trends in lung
cancer epidemiology. Emerging economies and developing countries face many challenges in initiating tobacco
cessation campaigns while also addressing environmental
risk factors and cultural barriers. Over the past three to
four decades, in contrast, industrialized nations have seen
large declines in cigarette smoking and, consequently,
lung cancer. However, despite knowledge gains in tumor
biology that have led to targeted therapies, mortality from
lung cancer remains high for most patients around the
world. Future directions must include improvements in
early detection and technological advances in genomics
and genetics to achieve a more personalized approach to
therapy and ultimately improve lung cancer survival.
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